News
![AstraZeneca: Wettbewerb durch Generika!](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
AstraZeneca: Wettbewerb durch Generika!
![Mylan NV kann sich über deutliche Umsatzsteigerung freuen!](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
Mylan NV kann sich über deutliche Umsatzsteigerung freuen!
![Mylan NV kann sich über deutliche Umsatzsteigerung freuen!](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
Mylan NV kann sich über deutliche Umsatzsteigerung freuen!
![AstraZeneca: Wettbewerb mit preisgünstigeren Generika drückt auf die Ergebnisse!](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
AstraZeneca: Wettbewerb mit preisgünstigeren Generika drückt auf die Ergebnisse!
![AstraZeneca: Wettbewerb mit preisgünstigeren Generika drückt auf die Ergebnisse!](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
AstraZeneca: Wettbewerb mit preisgünstigeren Generika drückt auf die Ergebnisse!
![GlaxoSmithKline und Alphabet-Tochter gründen Gemeinschaftsfirma](/assets/news/news4-fce0efe65d8ba787508ef718c0a20bed51e468dbc656c188c43e13f15b4a4f53.png)
GlaxoSmithKline und Alphabet-Tochter gründen Gemeinschaftsfirma
![GlaxoSmithKline und Alphabet-Tochter gründen Gemeinschaftsfirma](/assets/news/news4-fce0efe65d8ba787508ef718c0a20bed51e468dbc656c188c43e13f15b4a4f53.png)
GlaxoSmithKline und Alphabet-Tochter gründen Gemeinschaftsfirma
![Shire und Baxalta: Der große Tag rückt näher](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
Shire und Baxalta: Der große Tag rückt näher
![Amarin Plc (AMRN) Q1 2024 Earnings Call Transcript: https://g.foolcdn.com/editorial/images/1/featured-transcript-logo-template-2023-01-12.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeSt3V1E9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--9dfca4603c1fc3af5c96a68f8938e1fa8ce6aed8/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/featured-transcript-logo-template-2023-01-12.jpg?locale=us)
Amarin Plc (AMRN) Q1 2024 Earnings Call Transcript
Image source: The Motley Fool.
Amarin Plc (NASDAQ: AMRN)Q1 2024 Earnings CallMay 01, 2024, 8:00 a.m. ET
Operator
Source Fool.com
![Why Amarin Stock Was Rocketing Higher on Wednesday: https://g.foolcdn.com/editorial/images/771713/medical-professionals-conferring-in-a-hospial-corridor.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBL1JwYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--c118053377e0a032b2529889f99219eea6597811/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/medical-professionals-conferring-in-a-hospial-corridor.jpg?locale=us)
Why Amarin Stock Was Rocketing Higher on Wednesday
Any one-product company that receives good news about that product will likely attract investors. That was the case Wednesday with Amarin (NASDAQ: AMRN), which received very encouraging news about
![Is Viatris a Great Dividend Stock or Just a Value Trap?: https://g.foolcdn.com/editorial/images/768795/a-couple-reviewing-a-document-at-home.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeEZWYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--a4c290c7a54a7f52f02a23352b5eb262c496c574/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/a-couple-reviewing-a-document-at-home.jpg?locale=us)
Is Viatris a Great Dividend Stock or Just a Value Trap?
Viatris (NASDAQ: VTRS) is a large and diverse pharmaceutical business that spun off from Pfizer in 2020. The company's medications are in 165 countries and much of its business centers around
![Is Viatris a Great Dividend Stock or Just a Value Trap?: https://g.foolcdn.com/editorial/images/768795/a-couple-reviewing-a-document-at-home.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeEZWYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--a4c290c7a54a7f52f02a23352b5eb262c496c574/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/a-couple-reviewing-a-document-at-home.jpg?locale=us)
Is Viatris a Great Dividend Stock or Just a Value Trap?
Viatris (NASDAQ: VTRS) is a large and diverse pharmaceutical business that spun off from Pfizer in 2020. The company's medications are in 165 countries and much of its business centers around
![Amarin Plc (AMRN) Q4 2023 Earnings Call Transcript: https://g.foolcdn.com/editorial/images/1/featured-transcript-logo-template-2023-01-12.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeSt3V1E9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--9dfca4603c1fc3af5c96a68f8938e1fa8ce6aed8/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/featured-transcript-logo-template-2023-01-12.jpg?locale=us)
Amarin Plc (AMRN) Q4 2023 Earnings Call Transcript
Image source: The Motley Fool.
Amarin Plc (NASDAQ: AMRN)Q4 2023 Earnings CallFeb 29, 2024, 8:00 a.m. ET
Operator
Source Fool.com
![Why Amarin Stock Skyrocketed Today: https://g.foolcdn.com/editorial/images/760915/chart-indicating-gains.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMlFJYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--5d351467bb6c39731c9442a70747a5305a1030ce/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/chart-indicating-gains.jpg?locale=us)
Why Amarin Stock Skyrocketed Today
Shares of Amarin (NASDAQ: AMRN) skyrocketed 32.9% on Wednesday after the biopharmaceutical company announced strong preliminary fiscal fourth-quarter results, a new share-repurchase authorization
![Amarin Plc (AMRN) Q3 2023 Earnings Call Transcript: https://g.foolcdn.com/editorial/images/1/featured-transcript-logo-template-2023-01-12.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeSt3V1E9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--9dfca4603c1fc3af5c96a68f8938e1fa8ce6aed8/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/featured-transcript-logo-template-2023-01-12.jpg?locale=us)
Amarin Plc (AMRN) Q3 2023 Earnings Call Transcript
Image source: The Motley Fool.
Amarin Plc (NASDAQ: AMRN)Q3 2023 Earnings CallNov 01, 2023, 8:00 a.m. ET
Operator
Source Fool.com
![Ozempic Just Shrugged Off a Challenge From Viatris. What Does This Mean for Investors?: https://g.foolcdn.com/editorial/images/752405/scientist-looks-at-test-tube.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBd2pDYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--e3a4a023639d4b418f001db2a8ea416e9bfb7930/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/scientist-looks-at-test-tube.jpg?locale=us)
Ozempic Just Shrugged Off a Challenge From Viatris. What Does This Mean for Investors?
As you may have heard, Novo Nordisk (NYSE: NVO) makes Ozempic, the type 2 diabetes medication sweeping the globe and raking in billions in the process. Where there's a money-printing drug in ascent
![Ozempic Just Shrugged Off a Challenge From Viatris. What Does This Mean for Investors?: https://g.foolcdn.com/editorial/images/752405/scientist-looks-at-test-tube.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBd2pDYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--e3a4a023639d4b418f001db2a8ea416e9bfb7930/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/scientist-looks-at-test-tube.jpg?locale=us)
Ozempic Just Shrugged Off a Challenge From Viatris. What Does This Mean for Investors?
As you may have heard, Novo Nordisk (NYSE: NVO) makes Ozempic, the type 2 diabetes medication sweeping the globe and raking in billions in the process. Where there's a money-printing drug in ascent
![Viatris Just Sold Off 3 Key Segments. Is It Still a Buy?: https://g.foolcdn.com/editorial/images/749955/investor-considers-laptop-with-notebook.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMHV2YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--ac990fa355d26865cdf82c992fe65786f8fc3be6/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/investor-considers-laptop-with-notebook.jpg?locale=us)
Viatris Just Sold Off 3 Key Segments. Is It Still a Buy?
On Oct. 1, Viatris (NASDAQ: VTRS) made an announcement that's sure to shake up its fortunes. It's divesting nearly all of its over-the-counter (OTC) medicines, its entire women's healthcare segment
![Viatris Just Sold Off 3 Key Segments. Is It Still a Buy?: https://g.foolcdn.com/editorial/images/749955/investor-considers-laptop-with-notebook.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMHV2YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--ac990fa355d26865cdf82c992fe65786f8fc3be6/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/investor-considers-laptop-with-notebook.jpg?locale=us)
Viatris Just Sold Off 3 Key Segments. Is It Still a Buy?
On Oct. 1, Viatris (NASDAQ: VTRS) made an announcement that's sure to shake up its fortunes. It's divesting nearly all of its over-the-counter (OTC) medicines, its entire women's healthcare segment
![Could Viatris Stock Help You Become a Millionaire?: https://g.foolcdn.com/editorial/images/748876/rich-person-standing-next-to-a-jet-and-convertible.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeStoYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--e6c8734432fb7f8262ca5da8b8e050bf47bdf398/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/rich-person-standing-next-to-a-jet-and-convertible.jpg?locale=us)
Could Viatris Stock Help You Become a Millionaire?
If you're investing $25,000 in your stock portfolio, then getting that investment to be worth $1 million over time is no simple task. Odds are, you'll have to wait decades for that investment to
![Could Viatris Stock Help You Become a Millionaire?: https://g.foolcdn.com/editorial/images/748876/rich-person-standing-next-to-a-jet-and-convertible.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeStoYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--e6c8734432fb7f8262ca5da8b8e050bf47bdf398/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/rich-person-standing-next-to-a-jet-and-convertible.jpg?locale=us)
Could Viatris Stock Help You Become a Millionaire?
If you're investing $25,000 in your stock portfolio, then getting that investment to be worth $1 million over time is no simple task. Odds are, you'll have to wait decades for that investment to
![Want to Collect $500 in Dividends Every Month? Invest $90,000 in These 3 Stocks: https://g.foolcdn.com/editorial/images/747177/a-couple-counting-money.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMFdSYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--0b5fa16450ddf1773099e340a348828170a3fe29/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/a-couple-counting-money.jpg?locale=us)
Want to Collect $500 in Dividends Every Month? Invest $90,000 in These 3 Stocks
Inflation is giving investors more of an incentive to find ways to increase their income. If you have a decent nest egg saved up, you can use it to invest in dividend stocks to improve your
![Want to Collect $500 in Dividends Every Month? Invest $90,000 in These 3 Stocks: https://g.foolcdn.com/editorial/images/747177/a-couple-counting-money.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMFdSYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--0b5fa16450ddf1773099e340a348828170a3fe29/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/a-couple-counting-money.jpg?locale=us)
Want to Collect $500 in Dividends Every Month? Invest $90,000 in These 3 Stocks
Inflation is giving investors more of an incentive to find ways to increase their income. If you have a decent nest egg saved up, you can use it to invest in dividend stocks to improve your
![Viatris Stock: Bear vs. Bull: https://g.foolcdn.com/editorial/images/745483/two-investors-consider-a-laptop.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBL3FDYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--1ccc0cc4deaa30a8b6e7f3f3c2816a28a86fb0ba/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/two-investors-consider-a-laptop.jpg?locale=us)
Viatris Stock: Bear vs. Bull
If you're wondering whether to buy Viatris (NASDAQ: VTRS) stock this fall, it's important to know the arguments for why it might gain value as well as why it's not the best option.
Generic drug
![Viatris Stock: Bear vs. Bull: https://g.foolcdn.com/editorial/images/745483/two-investors-consider-a-laptop.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBL3FDYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--1ccc0cc4deaa30a8b6e7f3f3c2816a28a86fb0ba/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/two-investors-consider-a-laptop.jpg?locale=us)
Viatris Stock: Bear vs. Bull
If you're wondering whether to buy Viatris (NASDAQ: VTRS) stock this fall, it's important to know the arguments for why it might gain value as well as why it's not the best option.
Generic drug